Feasibility, Fidelity, and Effectiveness of Administering Long-Acting Cabotegravir + Rilpivirine in Infusion Centers in the United States: Findings From the Phase 4 GLACIER Implementation Study

Background GLACIER (Giving Long-Acting Cabotegravir plus rilpivirine [CAB + RPV LA] in an Infusion Center [IC]) is a Phase 4 implementation study evaluating the perspective of people living with HIV-1 (participants) and IC staff on CAB + RPV LA delivery at ICs over 8 months. Methods Participants and...

Full description

Bibliographic Details

Main Authors:	Cassidy A. Gutner PhD, Conn Harrington BA, Gilda Bontempo MD, Sivakumar Pazhamalai BPharm, Abhishek Kumar MSc, Kelly Rimler MS, Karen Davis MS, RN, Will Williams BS, Deanna Merrill PharmD, MBA, AAHIVP, Lisa Petty MT (ASCP), Cindy Garris MS, Supriya Sarkar PhD, MPH, Patrick Daniele MS, Bridget Gaglio PhD, MPH, Katie May BSN, Michael Aboud MBChB, Maggie Czarnogorski MD, MPH
Format:	Artigo
Language:	Inglês
Published:	SAGE Publishing 2026-05-01
Series:	Journal of the International Association of Providers of AIDS Care
Online Access:	https://doi.org/10.1177/23259582261439585
Tags:	Add Tag No Tags, Be the first to tag this record!